Glenmark Pharmaceuticals Ltd. NSE: GLENMARK | BSE: 532296

Strong Performer, Getting Expensive

Download real time

2051.90 0.00 (0.00%)

60.87% Gain from 52W Low

866.4K

NSE+BSE Volume

NSE 08 Sep, 2025 3:31 PM (IST)

Dividend

Glenmark Pharmaceuticals Ltd. has an upcoming dividend of ₹2.50 per share due on 15 Sep 2025 See details

Glenmark Pharmaceuticals Ltd. share price target

Glenmark Pharmaceuticals Ltd. has an average share price target of 1997.50. The consensus estimate represents a downside of -2.65% from the last price of 2051.90. View 10 reports from 5 analysts offering long-term price targets for Glenmark Pharmaceuticals Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	09 Sep 2025	Glenmark Pharma	Consensus Share Price Target	2051.90	2246.45	-	9.48	buy	pdf Detailed Estimates
	15 Aug 2022	Glenmark Pharma	ICICI Securities Limited Reco Target	2051.90	478.00	388.80 (427.75%)	Target met	Buy	pdf post cache		Broker Report High base and weak US sales hit performance ICICI Securities Limited Glenmark Pharma’s (Glenmark) Q1FY23 performance missed our estimates. pdf Copy Link Share on Share on Share on Share on Alert
	13 Aug 2022	Glenmark Pharma	Motilal Oswal	2051.90	420.00	389.25 (427.14%)	Target met	Neutral	pdf post cache		Broker Report Steady traction exhibited in DF/ROW Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	07 Jun 2022	Glenmark Pharma	Geojit BNP Paribas Reco Target	2051.90	485.00	388.45 (428.23%)	Target met	Buy	pdf post cache		Broker Report GLENMARK PHARMACEUTICALS Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Glenmark Pharma	Prabhudas Lilladhar Target	2051.90	450.00	389.10 (427.35%)	Target met	Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	31 May 2022	Glenmark Pharma	Motilal Oswal Target	2051.90	420.00	393.55 (421.38%)	Target met	Neutral	pdf post cache		Broker Report US remains a drag on overall performance Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	15 Feb 2022	Glenmark Pharma	Prabhudas Lilladhar Target	2051.90	550.00	487.20 (321.16%)		Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTI Prabhudas Lilladhar Strong revenue growth across India, EU and RoW markets: Revenue grew 14% YoY to Rs31.7bn vs our est of Rs31bn. During Q3, Ichnos entered into an exclusive licensing agreement with Almirall SA and received upfront payment of EURO20.8mn. Adjusted for this revenue growth was 7% YoY. India formulations grew strongly by 14%. US growth was flat QoQ to US$101mn. LATAM sales declined by 9% YoY due to pandemic challenges in Brazil. Robust growth in RoW of 24% YoY, aided by strong traction in Ryaltris. EU... pdf Copy Link Share on Share on Share on Share on Alert
	14 Feb 2022	Glenmark Pharma	ICICI Securities Limited Target	2051.90	550.00	478.30 (329.00%)		Hold	pdf post cache		Broker Report Glenmark Pharmaceuticals ICICI Securities Limited Innovation new company (ICHNOS) to focus on discovery and development of novel, firstinclass treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs Q3FY22 Results: Glenmark reported strong numbers in India, Europe and RoW... pdf Copy Link Share on Share on Share on Share on Alert
	18 Nov 2021	Glenmark Pharma	Geojit BNP Paribas Reco Target	2051.90	575.00	482.60 (325.18%)		Accumulate	pdf post cache		Broker Report GLENMARK PHARMACEUTICALS Geojit BNP Paribas Glenmark Pharma Ltd (GNP) is an India-based pharmaceutical company with commercial presence in more than 80 countries across the globe. GNP is primarily focused on generics, specialty and OTC businesses. The company has strong regional/country-specific presence in diabetes,... pdf Copy Link Share on Share on Share on Share on Alert
	16 Nov 2021	Glenmark Pharma	Prabhudas Lilladhar Target	2051.90	600.00	501.40 (309.23%)		Accumulate	pdf post cache		Broker Report Q2FY22 Result Update - In-line quarter; US sales and out-licensing holds key - ACCUMULATE Prabhudas Lilladhar Ryaltris to be major growth driver in FY23. Glenmark Pharma (GNP) has been able to maintain EBITDA run-rate on a high base. Given flat R&D expense and limited capex requirements, debt will continue to fall in FY23. While, pick up in US sales will be key to drive earnings growth. We have factored in 12% EPS CAGR over FY21-24E. In the near term, any potential out-licensing deals in Ichnos will be key for any further meaningful reduction in debt. At CMP, stock is trading at 13x FY23E P/E. We... pdf Copy Link Share on Share on Share on Share on Alert
	15 Nov 2021	Glenmark Pharma	ICICI Securities Limited Reco Target	2051.90	580.00	535.75 (283.00%)		Hold	pdf post cache		Broker Report Glenmark Pharmaceuticals ICICI Securities Limited In India, it is the market leader in dermatology and improving its presence in respiratory, CVS, anti-infectives and anti-diabetics, in particular. It has also forayed into consumer health segment focusing on Rx-OTC switch products (~\| 150 crore) led by two brands, Candid and Scalpe+ Progress on the margins front amid cost rationalisation measures and decline in R&D expenses as percentage of sales... pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners